This trial is studying taletrectinib to see how well it works in treating patients with non-small cell lung cancer.
- Non-Small Cell Lung Cancer
1 Primary · 5 Secondary · Reporting Duration: Up to 4 years
1 Treatment Group
1 of 1
154 Total Participants · 1 Treatment Group
Primary Treatment: Taletrectinib · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 14 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
|18 - 65||100.0%|
What site did they apply to?
|American Institute of Research||100.0%|
What portion of applicants met pre-screening criteria?
Frequently Asked Questions
Are there any openings for new participants in this trial?
"Absolutely. Evidence from clinicaltrials.gov confirms that this research, which was first published on September 1st 2021, is still recruiting subjects. A total of 119 participants are needed across 25 distinct medical sites." - Anonymous Online Contributor
What is the scope of enrolment for this research project?
"AnHeart Therapeutics Inc. need to enlist 119 participants that meet their study's criteria, and are running the trial from multiple sites such as Keck Medicine of University of Southern California in LA and Moores Cancer Center at UC San Diego in La Jolla, Minnesota." - Anonymous Online Contributor
What deleterious effects have been observed when taking Taletrectinib?
"We at Power assign a safety rating of 2 to taletrectinib, as there is some evidence backing its safe use but none that speaks to efficacy." - Anonymous Online Contributor
How many healthcare settings are participating in this trial?
"This trial has 25 active clinical sites including Keck Medicine of University of Southern California in Los Angeles, Moores Cancer Center at UC San Diego in La Jolla and Mayo Clinic in Rochester. Additionally, there are 22 other operating centres." - Anonymous Online Contributor